22 completed, 10 active not recruiting, 9 terminated, 4 recruiting. 33 Phase 2, 22 Phase 1, 1 Phase 3.
Follow this condition Literature Review of Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome trials Research Report on Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Completed | Roswell Park Cancer Institute | 21 | 2021-07-29 | 2026-09-08 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 1 | 2021-05-21 | 2026-05-20 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2021-02-17 | 2026-06-12 |
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia Azacitidine, Biopsy Procedure, Biospecimen Collection - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2021-02-16 | 2026-08-03 |
| Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia Cytarabine, Idarubicin Hydrochloride, Navtemadlin - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2021-02-04 | 2026-06-11 |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation Biospecimen Collection, Bone Marrow Aspiration, Olaparib - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2020-08-04 | 2026-09-10 |
| Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | Jennifer Saultz | 51 | 2019-08-16 | 2026-09-24 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2019-07-10 | 2026-06-22 |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Fludarabine Phosphate - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2019-05-17 | 2025-04-13 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 72 | 2019-01-31 | 2026-09-18 |
| Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 48 | 2018-11-29 | 2026-05-20 |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 50 | 2018-11-07 | 2026-07-24 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy Edetate Calcium Disodium, Multivitamin, Succimer - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 58 | 2018-10-11 | 2026-09-18 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Carboplatin, Topotecan, Topotecan Hydrochloride - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 25 | 2018-09-24 | 2026-06-23 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Terminated | University of Southern California | 3 | 2018-05-09 | 2021-11-30 |
| Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Cytarabine, Idarubicin, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 53 | 2018-04-18 | 2026-06-01 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Decitabine, Laboratory Biomarker Analysis, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 235 | 2018-01-18 | 2026-03-10 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 75 | 2017-10-24 | 2026-06-22 |
Showing 20 of 47. Sign in to see all of them.
Leukemia, Myeloid, Acute (41) · Leukemia, Myelomonocytic, Chronic (20) · Myelodysplastic Syndromes (15) · Leukemia, Myelomonocytic, Acute (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Anemia, Refractory, with Excess of Blasts (6) · Leukemia, Biphenotypic, Acute (6) · Blast Crisis (5) · Leukemia, Erythroblastic, Acute (5) · Leukemia, Megakaryoblastic, Acute (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Leukemia, Monocytic, Acute (4) · Hodgkin Disease (3) · Leukemia, Myeloid, Accelerated Phase (3) · Leukemia, Promyelocytic, Acute (3)
Hematologic Diseases (43) · Hemic and Lymphatic Diseases (43) · Leukemia (43) · Leukemia, Myeloid (43) · Neoplasms (43) · Neoplasms by Histologic Type (43) · Bone Marrow Diseases (28) · Chronic Disease (23) · Disease Attributes (23) · Pathologic Processes (23) · Pathological Conditions, Signs and Symptoms (23) · Myelodysplastic-Myeloproliferative Diseases (19) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12)
Cytarabine (13) · Azacitidine (11) · Injections (8) · Tacrolimus (8) · fludarabine phosphate (8) · Whole-Body Irradiation (7) · Cyclophosphamide (6) · Peripheral Blood Stem Cell Transplantation (6) · Biopsy (5) · CPX-351 (5) · Mycophenolic Acid (5) · venetoclax (5) · Busulfan (4) · Daunorubicin (4) · Idarubicin (4)
M.D. Anderson Cancer Center (16) · National Cancer Institute (NCI) (16) · Fred Hutchinson Cancer Center (4) · University of Southern California (3) · City of Hope Medical Center (2) · Albert Einstein College of Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Jennifer Saultz (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · Vanderbilt-Ingram Cancer Center (1)
United States (45) · Canada (1) · Israel (1) · Peru (1)
Naval Daver (3) · Amer M Zeidan (2) · Samer Srour (2) · Tapan M Kadia (2) · Abhishek Maiti, MBBS (1) · Akil Merchant, MD (1) · Amanda Olson (1) · B. Smith (1) · Branko Cuglievan (1) · Brenda M. Sandmaier (1) · Casey O'Connell, MD (1) · Ehab L Atallah (1) · Eunice Wang, MD (1) · Gail J Roboz (1) · Ghayas Issa (1)
PMID 26527780, PMID 26577691, PMID 30335787, PMID 30567725, PMID 31171508, PMID 32092139, PMID 32777116, PMID 32896301, PMID 33027528, PMID 33394722, PMID 33580980, PMID 33609248, PMID 33792630, PMID 34255353, PMID 34312462, PMID 34474640, PMID 34980577, PMID 35420672, PMID 36184192, PMID 36384181, PMID 37939122, PMID 38391202, PMID 42007254, PMID 42835577
P30CA016672 (5), P30CA014089 (3), U10CA180820 (3), U10CA180821 (3), UM1CA186689 (3), UM1CA186691 (3), P01CA078902 (2), P30CA006973 (2), P30CA013330 (2), U01CA070095 (2), U10CA021115 (2), U10CA031946 (2), N01CM00032 (1), N01CM00071 (1), N01CM17103 (1)